Ludwig Enterprises (Ludwig Enterprises) Interest Expense : $-0.12 Mil (TTM As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Ludwig Enterprises Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Ludwig Enterprises's interest expense for the three months ended in Mar. 2024 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.12 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Ludwig Enterprises's Operating Income for the three months ended in Mar. 2024 was $ -0.40 Mil. Ludwig Enterprises's Interest Expense for the three months ended in Mar. 2024 was $ -0.02 Mil. Ludwig Enterprises did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ludwig Enterprises Interest Expense Historical Data

The historical data trend for Ludwig Enterprises's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ludwig Enterprises Interest Expense Chart

Ludwig Enterprises Annual Data

Trend

Dec22

Dec23

Interest Expense

-0.45

-0.49

Ludwig Enterprises Quarterly Data
	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial			-0.15	-0.16	-0.07	-0.04	-0.02

Ludwig Enterprises Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.

Ludwig Enterprises (OTCPK:LUDG) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Ludwig Enterprises's Interest Expense for the three months ended in Mar. 2024 was $-0.02 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-0.40 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.00 Mil.

Ludwig Enterprises's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Ludwig Enterprises did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Ludwig Enterprises (Ludwig Enterprises) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ludwig Enterprises Inc (OTCPK:LUDG) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1749 VICTORIAN AVENUE, Suite C-350, Sparks, NV, USA, 89431

Website

https://www.ludwigent.com

Ludwig Enterprises Inc is a publicly traded Medical Technology Holding Company with Precision Genomics, Inc. and MyRNA for Life, Inc. as wholly owned subsidiaries. The company's advancements in medical technology and Artificial Intelligence (AI) have awarded it with cutting-edge genomic tools. These genomic tools have the potential to detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era with their proprietary mRNA genetic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including but not limited to heart disease, diabetes, preeclampsia, and cancer. It manages its business on the basis of one operating and reportable segment.